

### This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
<b>Cancer</b>				
Colon cancer	CXC chemokine receptor 2 (CXCR2; IL8RB)	<p>Mouse studies suggest antagonizing CXCR2 could help treat or prevent colitis-associated colon cancer. In a mouse model of colitis-associated colon cancer, <i>Cxcr2</i> knockout mice had less chronic colon inflammation, infiltration of granulocytic myeloid-derived suppressor cells (MDSCs) into the colon and tumorigenesis than unaltered mice. In the <i>Cxcr2</i><sup>-/-</sup> mice, adoptive transfer of MDSCs from wild-type mice restored the colitis-induced tumorigenesis. Next steps could include testing CXCR2 antagonists in the mouse model.</p> <p>Dompe Farmaceutici S.p.A. has the CXCR2 antagonist reparixin in Phase III testing to treat graft rejection.</p> <p>At least four other companies have CXCR2 antagonists in Phase II/III or earlier testing for various indications.</p> <p><b>SciBX 7(1); doi:10.1038/scibx.2014.11</b>  <b>Published online Jan. 9, 2014</b></p>	Patent and licensing status unavailable	<p>Katoh, H. <i>et al. Cancer Cell</i>; published online Nov. 11, 2013; doi:10.1016/j.ccr.2013.10.009</p> <p><b>Contact:</b> Raymond N. DuBois, Biodesign Institute at Arizona State University, Tempe, Ariz.            e-mail: <a href="mailto:duboisrn@asu.edu">duboisrn@asu.edu</a></p>